ProCE Banner Activity

PALOMA-3: Phase III Noninferiority Trial of SC Amivantamab vs IV Amivantamab Each With Lazertinib in Progressive Advanced EGFR-Mutated NSCLC

Conference Coverage
Slideset

Primary analysis of the phase III PALOMA-3 trial of SC vs IV amivantamab, both in combination with lazertinib, demonstrated noninferior pharmacokinetics and ORR, plus a lower rate of infusion-related reactions with SC amivantamab, in patients with advanced EGFR-mutated NSCLC and disease progression on or after osimertinib and platinum-based chemotherapy.

Released: June 04, 2024

Expiration: June 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.